Comparative Pharmacology
Head-to-head clinical analysis: MARINOL versus METOZOLV ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARINOL versus METOZOLV ODT.
MARINOL vs METOZOLV ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronabinol is a cannabinoid receptor agonist at CB1 and CB2 receptors. It stimulates appetite and reduces nausea/vomiting via central CB1 receptor activation.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
Dronabinol (Marinol) 2.5 mg orally twice daily, titrated to 5–20 mg daily in divided doses; max 20 mg/day. For chemotherapy-induced nausea/vomiting: 5 mg/m² orally 1–3 hours before chemotherapy, then every 2–4 hours up to 6 doses/day. For anorexia: 2.5 mg orally twice daily (before lunch and dinner).
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
None Documented
None Documented
Dronabinol terminal half-life is 25–36 hours in adults, with a prolonged elimination phase (25–36 h) due to enteric recirculation. Chronic users may exhibit a shorter half-life due to enzyme induction.
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (65%) with biliary excretion; renal excretion of metabolites accounts for ~20% (mostly as glucuronide conjugates). Less than 5% of unchanged drug is excreted renally.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Antiemetic
Antiemetic